Morgan Stanley Maintains Equal-Weight on NeoGenomics, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on NeoGenomics (NASDAQ:NEO) and raised the price target from $16 to $17.
November 08, 2023 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on NeoGenomics and raised the price target from $16 to $17.
The news is directly related to NeoGenomics and is likely to have a positive impact on its stock price in the short term. The increase in the price target by a reputable financial institution like Morgan Stanley indicates a positive outlook for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100